Caribou Biosciences (NASDAQ:CRBU) Stock Rating Upgraded by Truist Financial

Key Points

• Truist upgraded Caribou Biosciences to a "strong‑buy" while Weiss Ratings maintained a "sell (d‑)", leaving the consensus at a "Moderate Buy" with an average target price of $8.00.
• Caribou beat the latest quarter's estimates (EPS -$0.28 vs. -$0.33; revenue $3.94M vs. $1.96M) but remains unprofitable with steep negative margins and analysts forecast about -$1.64 EPS for the fiscal year.
• Caribou is a clinical‑stage CRISPR gene‑editing company, co‑founded by Nobel laureate Jennifer Doudna, developing engineered T‑cell/NK therapies and in vivo editing programs for cancers and monogenic disorders.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) was upgraded by equities researchers at Truist Financial to a "strong-buy" rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Caribou Biosciences in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Caribou Biosciences presently has an average rating of "Moderate Buy" and an average target price of $8.00.

Caribou Biosciences Stock Up 3.3%

CRBU opened at $1.88 on Wednesday. The firm has a market capitalization of $181.68 million, a P/E ratio of -1.18 and a beta of 2.54. The stock has a fifty day moving average of $1.71 and a 200-day moving average of $1.91. Caribou Biosciences has a 12-month low of $0.66 and a 12-month high of $3.54.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.05. The business had revenue of $3.94 million for the quarter, compared to the consensus estimate of $1.96 million. Caribou Biosciences had a negative return on equity of 78.40% and a negative net margin of 1,327.40%. On average, analysts expect that Caribou Biosciences will post -1.64 earnings per share for the current fiscal year.

Institutional Trading of Caribou Biosciences

A number of institutional investors have recently bought and sold shares of the company. Envestnet Asset Management Inc. increased its position in Caribou Biosciences by 626.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 318,657 shares of the company's stock worth $402,000 after purchasing an additional 274,812 shares during the last quarter. Aberdeen Group plc lifted its holdings in shares of Caribou Biosciences by 54.7% during the 3rd quarter. Aberdeen Group plc now owns 1,388,905 shares of the company's stock valued at $3,236,000 after buying an additional 491,326 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Caribou Biosciences by 577.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 74,053 shares of the company's stock valued at $93,000 after buying an additional 63,129 shares during the last quarter. US Bancorp DE grew its stake in shares of Caribou Biosciences by 18,624.0% in the 3rd quarter. US Bancorp DE now owns 34,265 shares of the company's stock valued at $80,000 after buying an additional 34,082 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new stake in shares of Caribou Biosciences in the 1st quarter valued at approximately $61,000. Institutional investors and hedge funds own 77.51% of the company's stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company's core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.